Overview
Succinyl-CoA ligase ADP-forming subunit beta (SUCLA2) is a mitochondrial enzyme that catalyzes a critical step in cellular energy metabolism. Encoded by the SUCLA2 gene located on chromosome 13q14.2, this protein functions as the beta (regulatory) subunit of the succinyl-CoA ligase complex, also known as succinate thiokinase. SUCLA2 catalyzes the reversible conversion of succinyl-CoA and ADP (or GDP) to succinate and ATP (or GTP), playing an essential role in both the tricarboxylic acid (TCA) cycle and cellular energy homeostasis. Mutations in SUCLA2 are associated with mitochondrial disease and progressive neurological dysfunction, making this enzyme a key focus in neurodegenerative disease research.
Function/Biology
SUCLA2 operates as part of the ATP-forming subunit of the succinyl-CoA ligase complex, which exists in multiple isoforms with tissue-specific distribution. The enzyme catalyzes substrate-level phosphorylation, a direct mechanism of ATP generation that complements oxidative phosphorylation. At the molecular level, SUCLA2 exhibits nucleotidyl transferase activity, utilizing succinyl-CoA as the substrate and producing succinate, which feeds into the TCA cycle as a four-carbon intermediate.
...Overview
Succinyl-CoA ligase ADP-forming subunit beta (SUCLA2) is a mitochondrial enzyme that catalyzes a critical step in cellular energy metabolism. Encoded by the SUCLA2 gene located on chromosome 13q14.2, this protein functions as the beta (regulatory) subunit of the succinyl-CoA ligase complex, also known as succinate thiokinase. SUCLA2 catalyzes the reversible conversion of succinyl-CoA and ADP (or GDP) to succinate and ATP (or GTP), playing an essential role in both the tricarboxylic acid (TCA) cycle and cellular energy homeostasis. Mutations in SUCLA2 are associated with mitochondrial disease and progressive neurological dysfunction, making this enzyme a key focus in neurodegenerative disease research.
Function/Biology
SUCLA2 operates as part of the ATP-forming subunit of the succinyl-CoA ligase complex, which exists in multiple isoforms with tissue-specific distribution. The enzyme catalyzes substrate-level phosphorylation, a direct mechanism of ATP generation that complements oxidative phosphorylation. At the molecular level, SUCLA2 exhibits nucleotidyl transferase activity, utilizing succinyl-CoA as the substrate and producing succinate, which feeds into the TCA cycle as a four-carbon intermediate.
The SUCLA2 protein contains critical structural domains including a nucleotide-binding domain and an alpha-helical interface region that facilitates interaction with SUCLG2 (the catalytic alpha subunit). This heteromeric complex organization is essential for optimal enzymatic efficiency. The enzyme demonstrates coenzyme A (CoA) utilization, requiring Mg2+ as a cofactor. SUCLA2 expression is particularly prominent in tissues with high metabolic demands, including brain, heart, and skeletal muscle—tissues directly affected in neurodegenerative conditions.
Role in Neurodegeneration
Mutations in SUCLA2 cause a rare autosomal recessive mitochondrial disease characterized by progressive encephalomyopathy, developmental regression, and progressive neurological symptoms. The disease typically manifests in childhood with features including psychomotor regression, dystonia, seizures, hearing loss, and visual decline. Neuroimaging frequently reveals basal ganglia involvement and progressive cerebral atrophy, reflecting selective vulnerability of high-energy-demand neural structures.
The neurological manifestations reflect compromised cerebral energy metabolism, as neurons are particularly dependent on consistent ATP supply. Impaired succinyl-CoA ligase function reduces ATP production, disrupts TCA cycle function, and impairs redox balance within mitochondria. The accumulation of upstream metabolic intermediates can trigger oxidative stress through altered NADH/NAD+ ratios and electron transport chain dysfunction.
Molecular Mechanisms
SUCLA2 mutations reduce enzymatic activity through several mechanisms: disrupted protein folding, impaired cofactor binding, compromised nucleotide recognition, or destabilization of the heterocomplex with SUCLG2. Pathogenic variants identified include missense mutations affecting conserved residues within functional domains, deletions, and splice-site mutations.
At the cellular level, SUCLA2 deficiency causes TCA cycle impairment, leading to incomplete oxidation of acetyl-CoA, reduced NADH generation, and decreased electron transport chain function. This cascade reduces ATP synthesis and increases reactive oxygen species (ROS) production through electron leak at complex I and III. Accumulated succinyl-CoA may trigger alternative metabolic pathways, including increased ketone body metabolism or altered amino acid catabolism.
Mitochondrial quality control is compromised through reduced ATP availability for autophagy and mitophagy, leading to accumulation of dysfunctional mitochondria. Elevated ROS damages mtDNA, proteins, and lipids, triggering oxidative stress-mediated neuronal degeneration.
Clinical/Research Significance
SUCLA2-associated disease represents a tractable model for understanding primary mitochondrial dysfunction in neurodegeneration. Research has identified that disease severity correlates with residual enzyme activity, suggesting therapeutic potential for pharmacological chaperones or cofactor supplementation strategies. The identification of SUCLA2 mutations has refined diagnostic criteria for mitochondrial encephalomyopathies and expanded understanding of bioenergetic vulnerability in the nervous system.
Current investigations examine potential therapeutic interventions including CoA analogs, antioxidant strategies, and mitochondrial biogenesis enhancement through PGC-1α activation.
- SUCLG2 (Succinyl-CoA ligase alpha subunit)
- Tricarboxylic acid cycle
- Mitochondrial ATP synthesis
- Mitochondrial encephalomyopathy
- Succinyl-CoA metabolism
- Neuronal bioenergetics